Skip to content

Oral Immunonutrition With Synbiotics, Omega 3 and Vitamin D in Patients Undergoing Duodenopancreatectomy for Tumoral Lesion.

Standard Preoperative Oral Immunonutrition Versus Oral Immunonutrition With Synbiotics, Sustained Omega 3 Impregnation and Vitamin D in Patients Undergoing Duodenopancreatectomy for Tumoral Lesion : a Prospective, Placebo-controlled, Double-blind, Randomized Clinical Trial. The SIO3D Study.

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05271344
Acronym
SIO3D
Enrollment
74
Registered
2022-03-09
Start date
2022-04-08
Completion date
2026-03-31
Last updated
2023-09-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Complication,Postoperative, Pancreatic Cancer, Surgery

Keywords

synbiotics, omega 3, vitamin D, probiotics, prebiotics

Brief summary

The purpose of this trial is to demonstrate that synbioimmunonutrition (SI) combined with omega-3 fatty acids (O3) and Vitamin D (D) is superior to conventional 7-day preoperative immunonutrition in terms of reducing overall morbidity, in cases of duodenopancreatectomy for tumoral lesion.

Detailed description

To the best knowledge of the Investigators, a comprehensive multimodal approach to reduce postoperative morbidity in duodenopancreatectomies has not yet been evaluated. In the study, the Investigators combine the main nutritional interventions currently available and already having an individual scientific basis, sequentially and simultaneously, for a potential synergistic effect. In cases of duodenopancreatectomy for tumoral lesion, a group of patients taking only conventional immunonutrition regimen (CIR), for 7 preoperative days, will be compared with a second group where immunonutrition will be maximised by the addition of omega 3 for 1 week prior to the administration of CIR, synbiotics for 14 days pre- and post-operatively, and preoperative vitamin D supplementation for 6 days, in terms of postoperative overall morbidity.

Interventions

DIETARY_SUPPLEMENTNutritional Products

Omega 3 : 1 softgel, 3 x/d Probiotics : 1 caps / d Prebiotics : 1 measuring spoon of powder to be diluted in water, 1x/d Vitamin D : 1 tablet, 2x/d

Sponsors

Centre Hospitalier Universitaire de Liege
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* All cases of duodenopancreatectomy for tumoral lesions.

Exclusion criteria

* Distal or total pancreatectomies, as well as procedures for chronic pancreatitis * Patient refusal or inability to provide informed consent * Use of dietary supplements containing omega 3, pre- or probiotics within 15 days prior to protocol initiation * Severe cardiorespiratory or renal insufficiency * HIV * Cirrhosis Child-Pugh B-C * Inability to feed by mouth * Intestinal obstruction * Unresectable tumor or metastatic disease on preoperative work-up * Cardiac valvular pathology * Short bowell syndrome * Haemophilia * Known allergy or intolerance to fish oil, fish or shellfish, milk, soy or components of the products used * BMI \< 16kg/m2 * Weight loss \> 15% in the last 6 months * Little or no food in the last 10 days * Hypercalcemia * Pregnancy, breastfeeding

Design outcomes

Primary

MeasureTime frameDescription
Calculation of the Comprehensive Complication Index (CCI)From the Day of the operation to the patient's discharge Day of the hospital, up to 90 days after surgeryThis criterion takes into account all the complications of a given patient by weighting their relative importance. It varies from 0 to 100. A score of 0 means the absence of complications. A score of 100 is the death.

Secondary

MeasureTime frameDescription
Rate of infectious or non infectious complications and rate of mortalityup to 90 days after surgeryWound infection, pulmonary infection, urinary infection, intra-abdominal abscess, sepsis, pancreatic fistula, delayed gastric emptying, wound dehiscence, intestinal obstruction, intra-abdominal bleeding, pulmonary embolism, ...
Research of occult-bacterial translocation in blood samplesDay+1 and Day+4 postoperative dayq-PCR technique
Metagenomic characterization of the faecal microbiotaDay-19 (or Day-18, or Day-17, or Day-16) preoperative day and Day-1 preoperative dayMetagenomic sequencing through faecal samples
Blood determination of lipopolysaccharide binding proteinDay-19 (or Day-18, or Day-17, or Day-16) preoperative day and the day of the operationAs a measure of intestinal barrier integrity

Countries

Belgium

Contacts

Primary ContactAlain Pans, MD
a.pans@chuliege.be003243667216

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026